Search Results - "Chetty, Dushen"

A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia by Gubelin Harcha, Walter, MD, Barboza Martínez, Julia, MD, Tsai, Tsen-Fang, MD, Katsuoka, Kensei, MD, Kawashima, Makoto, MD, PhD, Tsuboi, Ryoji, MD, PhD, Barnes, Allison, MS, Ferron-Brady, Geraldine, PharmD, PhD, Chetty, Dushen, PhD

“…Background Dihydrotestosterone is the main androgen causative of androgenetic alopecia, a psychologically and physically harmful condition warranting medical…”
Get full text

A Phase 0 Study to Assess the Biodistribution and Pharmacokinetics of a Radiolabeled Antibody Targeting Human Kallikrein 2 in Participants with Metastatic Castration-Resistant Prostate Cancer by Pandit-Taskar, Neeta, O'Donoghue, Joseph A, Chetty, Dushen, Max, Steven, Wanik, Danielle, Ilovich, Ohad, Russell, Michael, Nyima, Tenzin, Divgi, Chaitanya R, Yu, Margaret, Morris, Michael J

“…Despite the inclusion of multiple agents within the prostate cancer treatment landscape, new treatment options are needed to address the unmet need for…”
Get full text

Pretherapeutic first-in-human targeting trial of anti-hK2 antibody h11B6: A potential molecular vector for alpha-particle radioimmunotherapy by Morris, Michael J., O' Donoghue, Joseph A., Chetty, Dushen, Max, Steven, Wanik, Danielle, Russell, Mike, Nyima, Tenzin, Avadhani, Anjali Narayan, Divgi, Chaitanya R, Pandit-Taskar, Neeta

“…Abstract only 122 Background: Radioligand therapy for metastatic castration resistant prostate cancer (mCRPC) has focused to date on targeting prostate…”
Get full text

Phase 0 study to assess [111In]-DOTA-h11B6 to target human kallikrein-2 (hk2) in men with metastatic castration-resistant prostate cancer by Morris, Michael J., O' Donoghue, Joseph A., Chetty, Dushen, Russell, Mike, Zulch, Emma, Avadhani, Anjali Narayan, Divgi, Chaitanya R., Pandit-Taskar, Neeta

“…Abstract only TPS249 Background: Human kallikrein-2 (hk2) is a member of the kallikrein family, is produced by prostatic epithelium, has 80% DNA sequence…”
Get full text

Abstract DDT02-04: A novel PRMT5 inhibitor with potent in vitro and in vivo activity in preclinical lung cancer models by Brehmer, Dirk, Wu, Tongfei, Mannens, Geert, Beke, Lijs, Vinken, Petra, Gaffney, Dana, Sun, Weimei, Pande, Vineet, Thuring, Jan-Willem, Millar, Hillary, Poggesi, Italo, Somers, Ivan, Boeckx, An, Parade, Marc, Heerde, Erika van, Nys, Thomas, Yanovich, Carol, Herkert, Barbara, Verhulst, Tinne, Jardin, Marc Du, Meerpoel, Lieven, Moy, Christopher, Diels, Gaston, Viellevoye, Marcel, Schepens, Wim, Poncelet, Alain, Linders, Joannes T., Lawson, Edward C., Edwards, James P., Chetty, Dushen, Laquerre, Sylvie, Lorenzi, Matthew V.

“…PRMT5 is a type II methyltransferase that specifically adds methyl groups to arginine as a long-lasting post-translational modification. The PRMT5/MEP50…”
Get full text

Pharmacokinetic Bioequivalence Studies of a Fixed-Dose Combination of Tamsulosin and Dutasteride in Healthy Volunteers by Fossler, Michael J., Collins, David A., Thompson, Meg M., Nino, Antonio, Bianco, Joseph J., Chetty, Dushen

“…Background and Objectives The combination of dutasteride and tamsulosin may be more effective for the treatment of symptomatic benign prostatic hyperplasia…”
Get full text

Evaluation of Critical Formulation Factors in the Development of a Rapidly Dispersing Captopril Oral Dosage Form by Lee, Kyoung-Jin, Kang, Anthony, Delfino, John J., West, Thomas G., Chetty, Dushen, Monkhouse, Donald C., Yoo, Jaedeok

“…Abstract New methods of manufacture have enabled the creation of novel dosage forms with unique rapid-dispersion properties. This study combines one such…”
Get full text